Meda Aktiebolag successfully amends MTN terms and conditions and exercises call option

Meda Aktiebolag has successfully amended the terms and conditions of two series of notes issued pursuant to its SEK 7,000,000,000 medium term notes programme and inserted an early redemption call option which it will exercise with immediate effect

Today, Meda Aktiebolag (the “ Company ”) held two noteholders’ meetings pursuant to the summons sent on 7 November 2017 to the noteholders of the:

(i) SE0005132180 – STIBOR 3M +2.85% 2013/2018 notes (the “ 2018 Notes ”); and

(ii) SE0005991635 – STIBOR 3M +1.65% 2014/2019 notes (the “ 2019 Notes ” and together, with the 2018 Notes, the “ Notes ”),

issued under the SEK 7,000,000,000 medium term notes programme of the Company originally established on 25 May 2012 (as updated on 31 July 2012, 12 May 2014 and 16 July 2015), for the purposes of approving an amendment to the terms and conditions of the Notes to insert an early redemption call option (the “ Call Option ”).

A sufficient number of noteholders were present in order for each noteholders’ meeting to be quorate and a requisite majority of the voting noteholders at each noteholders meeting voted in favour of approving the proposed amendment to the terms and conditions.

As at the date hereof, the terms and conditions of the Notes have been effectively amended and the Company has given notice to the noteholders of each series of Notes that it will exercise the Call Option in accordance with the amended terms and conditions.

For further information regarding the amended terms and conditions and the Call Option, please refer to Skandinaviska Enskilda Banken AB (publ) acting as Tabulation and Paying Agent.

The Tabulation and Paying Agent:

Skandinaviska Enskilda Banken AB (publ)
Stjärntorget 4
SE-106 40 Stockholm
Sweden
Tel: +46 (0)8 763 80 96
Email: sebtenderagent@seb.se
Attention: SEB Tender Agent

Solna, 6 December 2017

The Board of directors

Meda Aktiebolag


For further inquiries, please contact:

Melissa Trombetta, Head of Global Investor Relations, Mylan NV.
tel: +1 (917) 262-2958
Melissa.Trombetta@mylan.com

This is information that Meda Aktiebolag is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12:45 noon CET on 6 December 2017.

Meda Aktiebolag is a leading international specialty pharma company. Meda’s products are sold in more than 120 countries worldwide and the company is represented by its own organizations in close to 60 countries. Find out more, visit www.meda.se .

Tags:

About Us

Meda is one of Europe's leading specialty pharma companies, with focus on marketing and market-adapted product development. Long-term partnerships and acquisitions are fundamental factors in its strategy.

Subscribe

Documents & Links